We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect in Phase IIa Trial in Nocturia

News   Jul 09, 2009

 
Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect in Phase IIa Trial in Nocturia
 
 
 

RELATED ARTICLES

Zika Vaccine Clinical Trial Begins

News

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine.

READ MORE

HIV Therapy Reduces Virus and Boosts Immunity in Drug-Resistant Patients

News

A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy for patients who have run out of effective treatment options.

READ MORE

Effective Approach to Optimizing Medicinal Molecules Developed

News

Lobachevsky University scientists develop an effective approach to optimizing medicinal molecules, which will significantly accelerate and automate the process of prototype optimization to candidate molecules for subsequent preclinical testing.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE